241 related articles for article (PubMed ID: 38181713)
21. Cuproptosis scoring system to predict the clinical outcome and immune response in bladder cancer.
Song Q; Zhou R; Shu F; Fu W
Front Immunol; 2022; 13():958368. PubMed ID: 35990642
[TBL] [Abstract][Full Text] [Related]
22. A risk prognostic model for patients with esophageal squamous cell carcinoma basing on cuproptosis and ferroptosis.
Li J; Liu J; Li J; Feng A; Nie Y; Yang Z; Zhang W
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11647-11659. PubMed ID: 37405477
[TBL] [Abstract][Full Text] [Related]
23. Inhibiting the compensatory elevation of xCT collaborates with disulfiram/copper-induced GSH consumption for cascade ferroptosis and cuproptosis.
Zhang P; Zhou C; Ren X; Jing Q; Gao Y; Yang C; Shen Y; Zhou Y; Hu W; Jin F; Xu H; Yu L; Liu Y; Tong X; Li Y; Wang Y; Du J
Redox Biol; 2024 Feb; 69():103007. PubMed ID: 38150993
[TBL] [Abstract][Full Text] [Related]
24. Selected Flavonols Targeting Cell Death Pathways in Cancer Therapy: The Latest Achievements in Research on Apoptosis, Autophagy, Necroptosis, Pyroptosis, Ferroptosis, and Cuproptosis.
Wendlocha D; Kubina R; Krzykawski K; Mielczarek-Palacz A
Nutrients; 2024 Apr; 16(8):. PubMed ID: 38674891
[TBL] [Abstract][Full Text] [Related]
25. Revolutionizing breast cancer treatment: Harnessing the related mechanisms and drugs for regulated cell death (Review).
Ai L; Yi N; Qiu C; Huang W; Zhang K; Hou Q; Jia L; Li H; Liu L
Int J Oncol; 2024 May; 64(5):. PubMed ID: 38456493
[TBL] [Abstract][Full Text] [Related]
26. Progress and Challenges in Tumor Ferroptosis Treatment Strategies: A Comprehensive Review of Metal Complexes and Nanomedicine.
Su Y; Liu B; Wang B; Chan L; Xiong C; Lu L; Zhang X; Zhan M; He W
Small; 2024 Jun; 20(25):e2310342. PubMed ID: 38221682
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive analysis of cuproptosis-related genes and tumor microenvironment infiltration characterization in breast cancer.
Song S; Zhang M; Xie P; Wang S; Wang Y
Front Immunol; 2022; 13():978909. PubMed ID: 36341328
[TBL] [Abstract][Full Text] [Related]
28. Mitochondrial-Targeted Copper Delivery for Cuproptosis-Based Synergistic Cancer Therapy.
Deng J; Zhuang H; Shao S; Zeng X; Xue P; Bai T; Wang X; Shangguan S; Chen Y; Yan S; Huang W
Adv Healthc Mater; 2024 Mar; ():e2304522. PubMed ID: 38530073
[TBL] [Abstract][Full Text] [Related]
29. Copper metabolism and cuproptosis in human malignancies: Unraveling the complex interplay for therapeutic insights.
Abdullah KM; Kaushal JB; Takkar S; Sharma G; Alsafwani ZW; Pothuraju R; Batra SK; Siddiqui JA
Heliyon; 2024 Mar; 10(5):e27496. PubMed ID: 38486750
[TBL] [Abstract][Full Text] [Related]
30. Engineered Microbial Nanohybrids for Tumor-Mediated NIR II Photothermal Enhanced Ferroptosis/Cuproptosis and Immunotherapy.
Ruan Y; Zhuang H; Zeng X; Lin L; Wang X; Xue P; Xu S; Chen Q; Yan S; Huang W
Adv Healthc Mater; 2024 Feb; 13(4):e2302537. PubMed ID: 37742322
[TBL] [Abstract][Full Text] [Related]
31. Cuproptosis and its application in different cancers: an overview.
Xu L; Liu K; Wang F; Su Y
Mol Cell Biochem; 2023 Dec; 478(12):2683-2693. PubMed ID: 36914880
[TBL] [Abstract][Full Text] [Related]
32. Identification of cuproptosis and ferroptosis-related subgroups and development of a signature for predicting prognosis and tumor microenvironment landscape in hepatocellular carcinoma.
Yang BF; Ma Q; Hui Y; Gao XC; Ma DY; Li JX; Pei ZX; Huang BR
Transl Cancer Res; 2023 Dec; 12(12):3327-3345. PubMed ID: 38192999
[TBL] [Abstract][Full Text] [Related]
33. Cuproptosis-related signature predicts prognosis, immunotherapy efficacy, and chemotherapy sensitivity in lung adenocarcinoma.
Wu G; Hu Q; Chen H; He M; Ma H; Zhou L; Xu K; Ren H; Qi J
Front Oncol; 2023; 13():1127768. PubMed ID: 37007124
[TBL] [Abstract][Full Text] [Related]
34. Cuproptosis status affects treatment options about immunotherapy and targeted therapy for patients with kidney renal clear cell carcinoma.
Zhang G; Chen X; Fang J; Tai P; Chen A; Cao K
Front Immunol; 2022; 13():954440. PubMed ID: 36059510
[TBL] [Abstract][Full Text] [Related]
35. A novel ferroptosis-related gene signature associated with cuproptosis for predicting overall survival in breast cancer patients.
Zhang X; Zhang Q
Acta Biochim Pol; 2023 Nov; 70(4):875-884. PubMed ID: 37930188
[TBL] [Abstract][Full Text] [Related]
36. Cuproptosis-Related Ferroptosis genes for Predicting Prognosis in kidney renal clear cell carcinoma.
Luo G; Wang L; Zheng Z; Gao B; Lei C
Eur J Med Res; 2023 May; 28(1):176. PubMed ID: 37189176
[TBL] [Abstract][Full Text] [Related]
37. Research progress in cuproptosis in liver cancer.
Chen L; Liu D; Tan Y
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Sept 28; 48(9):1368-1376. PubMed ID: 38044648
[TBL] [Abstract][Full Text] [Related]
38. Cuproptosis illustrates tumor micro-environment features and predicts prostate cancer therapeutic sensitivity and prognosis.
Cheng B; Tang C; Xie J; Zhou Q; Luo T; Wang Q; Huang H
Life Sci; 2023 Jul; 325():121659. PubMed ID: 37011878
[TBL] [Abstract][Full Text] [Related]
39. Cuproptosis-Associated lncRNA Establishes New Prognostic Profile and Predicts Immunotherapy Response in Clear Cell Renal Cell Carcinoma.
Xu S; Liu D; Chang T; Wen X; Ma S; Sun G; Wang L; Chen S; Xu Y; Zhang H
Front Genet; 2022; 13():938259. PubMed ID: 35910212
[No Abstract] [Full Text] [Related]
40. Epigenetic regulation of diverse cell death modalities in cancer: a focus on pyroptosis, ferroptosis, cuproptosis, and disulfidptosis.
Zhou S; Liu J; Wan A; Zhang Y; Qi X
J Hematol Oncol; 2024 Apr; 17(1):22. PubMed ID: 38654314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
